Bepridil

Drug Profile

Bepridil

Alternative Names: angopril; Bapadin; Bepricor; CERM 1978; Cordium; ORG 5730; Vascor

Latest Information Update: 18 Nov 2009

Price : $50

At a glance

  • Originator RETI
  • Developer Daiichi Sankyo Company; Meda Pharmaceuticals; Organon Italia; Ortho-McNeil
  • Class Class IV antiarrhythmics; Ischaemic heart disorder therapies; Pyrrolidines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Calmodulin antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Angina pectoris; Tachycardia

Most Recent Events

  • 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 21 Feb 2002 A study has been added to the Arrhythmias pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top